KYORIN Pharmaceutical Co Ltd: Segment Analysis

KYORIN Pharmaceutical Co Ltd (Kyorin), formerly KYORIN Holdings Inc, is a pharmaceutical company that offers prescription medicines, generic drugs, quasi-drugs, reagents, intermediates and other products. It also sells diagnostic products and industrial chemicals. The company operates through a single reportable segment.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's R&D activities focus on developing products in the areas of respiratory, otolaryngology, urology, infectious disease, rare and intractable diseases. In FY2023, the company spent JPY10,903 million on R&D activities, which as a percentage of revenue stood at 9.6% and grew 22.5% YoY. Its pipeline products include KRP-R120, a fusion protein drug in Phase III clinical trials indicated for the treatment of inflammatory diseases such as pulmonary sarcoidosis; AKP-009, a novel androgen receptor modulator indicated for benign prostatic hyperplasia is in Phase II clinical trials. The company operates R&D facilities in the US, Germany, Japan. It also operates WATARASE Research Center which is equipped with state-of-the-art equipment and instruments, connects individual research capabilities, encouraging ease of communication between researchers. KYORIN seeks to work in partnership with other pharmaceutical companies to enhance its pipeline products. The company’s R&D partners include Chem, JEIL Pharmaceuticals, Ferring International, Senju Pharmaceutical, Eisai, Bristol-Myers Squibb, MediciNova, Merck & Co., Allergan, and Kissei Pharmaceutical, among others.